AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ATRC

AtriCure (ATRC) Q3 2026 Earnings Call Transcript

AtriCure (ATRC) reported Q3 2026 revenue of $154.5M, up 15% YoY. Open ablation franchise grew 17%, driven by EnCompass Clamp adoption. Appendage management increased 12%, led by AtriClip FLEX-Mini. Pain management revenue surged 33%, with cryoSPHERE MAX and cryoXT driving growth. The company is on track with clinical trials, including BoxX-NoAF, which aims to address postoperative atrial fibrillation.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 3:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AtriCure (ATRC) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ATRCBullishHigh
01

Why it matters

The earnings release offers fresh quantitative data that can influence short‑term price action and informs sector outlook.

02

Market read

First‑time earnings data for a niche medical‑device firm; relevant for traders focused on healthcare device stocks.

03

What to watch

Potential headwinds from emerging PFA catheter competition and regulatory scrutiny of new devices.

Relevance 7/10Novelty 8/10Timing: after‑hours earnings release

Background

AtriCure (ATRC) provided its Q3 2026 earnings call, highlighting clinical trial enrollment, FDA clearance, and segment revenue growth.

Company-level read

Ticker impact

$ATRCBullishHigh confidence
Context

Q3 2026 earnings call disclosed $154.5M revenue, 15% YoY growth and detailed segment performance.

Expected impact

potential modest upside as investors price in stronger‑than‑expected revenue and segment growth

Evidence & confidence

The disclosed revenue and growth rates are new, primary data that can move the stock in after‑hours trading.

Market effects

Sector

Positive signal for cardiac surgery device sector, may lift peers with similar product lines.

Regional

U.S. medical‑device market sees incremental growth from AtriCure's results.

Global

Limited to niche cardiac‑surgery segment; no broad market effect.

Counterpoint

What could challenge this read

If guidance falls short of market expectations, the stock could face short‑term pressure despite revenue growth.

Key entities

  • company
    AtriCure

    Medical‑device maker specializing in cardiac surgery ablation and left atrial appendage management.

Read at source← All news

StoryAtriCure reports strong third-quarter results and raises 2026 guidance

Also covered by

3 outlets

Related articles

$ATRCMed

AtriCure 3Q 2026: Revenue $154.45M, EPS $0.08— 10-Q Summary

AtriCure reported Q3 2026 revenue of $154.45M, up 15% YoY, and net income of $4.06M, reversing a prior-year loss. EPS was $0.08 vs. a loss of $0.01. Nine-month revenue rose 14%, led by U.S. growth. Pain management and open ablation revenue increased, while hybrid procedures declined. New product launches and clinical trial updates were announced.

tradingview.com
$ATRCHigh

BTIG raises AtriCure stock price target to $70 on strong Q3 results

BTIG raised its price target on AtriCure (ATRC) to $70 from $63, citing strong Q3 results. Revenue of $154.5M beat estimates, up 15.1% YoY. U.S. revenue grew 17%, while international revenue missed consensus. Adjusted EBITDA and EPS also exceeded expectations. AtriCure raised its 2026 revenue and earnings guidance. Shares are up 84% over the past year but may be overvalued, according to InvestingPro.

investing.com
$ATRCHighAI 8/10

What AtriCure (ATRC) Said on Its Q3 Earnings Call

AtriCure (ATRC) reported Q3 earnings, highlighting 34.6% U.S. pain management revenue growth to $28.1M. The company expects 2026 revenue of $606M-$610M and raised adjusted EBITDA guidance to $91M-$94M. Clinical trials are progressing, with BoxX-NoAF enrollment nearing completion. International revenue grew 5.8% to $26.4M, despite some headwinds.

finance.yahoo.com
$ATRCHigh

AtriCure: Q3 Earnings Snapshot

AtriCure Inc. (ATRC) reported Q3 net income of $4.1M, or 8 cents per share, up from a loss last year. Adjusted EPS was 17 cents. Revenue hit $154.5M, beating estimates. The company forecasts full-year EPS of 40-46 cents and revenue of $606M-$610M. Shares are up 53% YTD and 77% over 12 months.

finance.yahoo.com
$ATRCHigh

AtriCure Reports Third Quarter 2026 Financial Results

AtriCure, Inc. (ATRC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For immediate release November 3, 2026 AtriCure Reports Third Quarter 2026 Financial Results • Third Quarter 2026 worldwide revenue of $154.5 million, an increase of 15.0% year over year • Profitability expansion in the Third Quarter 2026, with net income of $4.1 mil

SEC EDGAR 8-K